DALLAS, Feb. 4, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced presentations at two upcoming medical meetings. Details of the presentations are as follows:
Bascom Palmer Eye Institute's 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting
Title: Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients with Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Results from a Long-Term Follow-Up Study (REMAIN)
Session Title: Inherited Retinal Degenerations
Session Date: Saturday, February 8, 2025
Session Time: 6:25 p.m. ET
Presenter: Allen Ho, MD, FACS, FASRS, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital, and Chief Medical Advisor of Nanoscope
Dr. Ho will participate in a panel discussion on inherited retinal dystrophies (IRDs), for several of which, Nanoscope is developing restorative treatments. As part of this, Dr. Ho will discuss 126-week data from Nanoscope's REMAIN long-term follow-up study of advanced retinitis pigmentosa patients dosed in the RESTORE randomized controlled trial.
The Macula Society 48th Annual Meeting
Title: Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Topline Results from the REMAIN Follow-Up Study (REMAIN)
Session Title: Inherited Retinal Dystrophy I
Session Date: Thursday, February 13, 2025
Session Time: 7:05 a.m. ET
Presenter: Victor Gonzalez, MD, Gulf Coast Eye Institute and REMAIN trial investigator
Dr. Gonzalez will present and discuss long-term follow-up efficacy and safety data of Nanoscope's MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.
Investor
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
